Heron Therapeutics, Inc. /de/
A biotech company that makes drugs for pain after surgery and for nausea and vomiting tied to chemotherapy. Its U.S.-marketed products include ZYNRELEF, a long-acting local anesthetic for postoperative pain, and CINVANTI and SUSTOL, anti-nausea medicines given to chemotherapy patients. Founded in 1983, the company ran for decades as A.P. Pharma before renaming itself Heron Therapeutics in 2014 as part of a fresh strategic direction and a relisting on the Nasdaq.
Bought 2.39M
Granted 123.7K · Bought 4.25M
Granted 535.6K · Bought 150.0K
Granted 144.4K · Bought 85.0K
Granted 142.6K · Bought 75.0K
Granted 102.5K
Granted 136.8K
Granted 80.9K
Granted 64.9K
Granted 134.9K · Sold 600
Granted 134.9K · Sold 500
Granted 91.8K
Granted 134.9K
Granted 109.8K
Granted 49.0K
Granted 36.1K
Granted 41.9K
Granted 36.1K · Sold 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rosen David Efraim +1 co-filer10% owner · 2 transactions | — | 30.05M | — | 2.39M | — |
| Morgan AdamDirector · 6 transactions | — | 8.88M | 123.7K | 4.25M | — |
| Collard Craig AChief Executive Officer, Director · 21 transactions | — | 757.9K | 535.6K | 150.0K | — |
| Duarte IraEVP, Chief Financial Officer · 21 transactions | — | 264.6K | 144.4K | 85.0K | — |
| Forbes William PEVP, Chief Development Officer · 20 transactions | — | 221.6K | 142.6K | 75.0K | — |
| Quart Barry DChief Executive Officer, Director · 19 transactions | +77.3% | 178.0Kas of Jan 2023 | 102.5K | — | — |
| Hensley Mark EarlChief Operating Officer · 2 transactions | — | 136.8K | 136.8K | — | — |
| Rodriguez SusanDirector · 4 transactions | — | 87.2Kas of Jan 2025 | 80.9K | — | — |
| Peraza LisaVP, Chief Accounting Officer · 31 transactions | +298.6% | 55.9Kas of Jan 2024 | 64.9K | — | — |
| Christian WaageDirector · 7 transactions | +1320% | 54.0K | 134.9K | — | 600 |
| Johnson Craig ADirector · 7 transactions | +1515.6% | 54.0K | 134.9K | — | 500 |
| Cusack ThomasDirector · 2 transactions | — | 54.0K | 91.8K | — | — |
| Dissanaike SharmilaDirector · 5 transactions | — | 54.0K | 134.9K | — | — |
| Kaseta MichaelDirector · 3 transactions | — | 54.0K | 109.8K | — | — |
| Davis StephenDirector · 2 transactions | +1634.4% | 52.0Kas of Dec 2022 | 49.0K | — | — |
| Poyhonen JohnPresident & CCO · 21 transactions | +119.2% | 48.7Kas of Apr 2023 | 36.1K | — | — |
| Szekeres David LeslieEVP, Chief Operating Officer · 25 transactions | +1030.4% | 35.8Kas of Jul 2023 | 41.9K | — | — |
| Manhard KimberlyEVP, Drug Development · 23 transactions | +1113.7% | 29.7Kas of Apr 2023 | 36.1K | — | 1.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +6.95M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.